Uso da clofazimina no pioderma gangrenoso: a propósito de um caso

Campbell, Gladys; Campbell, Iphis; Leite, Rubens M. S; Batista, Márcia de S.
An. bras. dermatol ; 68(5): 287-90, set.-out. 1993. ilus, tab
Artículo en Portugués | LILACS | ID: lil-126819

Documentos relacionados

  1. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
  2. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
  3. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.
  4. Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches.
  5. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis.
  6. Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.
  7. Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics.
  8. Clofazimine-Loaded Mucoadhesive Nanoparticles Prepared by Flash Nanoprecipitation for Strategic Intestinal Delivery.
  9. [Pyoderma gangrenosum: 2 cases with perineal localization].
  10. Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.